Skip to main content

Table 2 The liver function tests in serum of control and NAFLD groups

From: The role of hepatic transcription factor cAMP response element-binding protein (CREB) during the development of experimental nonalcoholic fatty liver: a biochemical and histomorphometric study

Weeks ALT AST GGT Total bilirubin Direct bilirubin
  Control NAFLD Control NAFLD Control NAFLD Control NAFLD Control NAFLD
2 10.6 ± 1.29 18.6 ± 0.51* 12.2 ± 1.02 21.6 ± 1.21* 9.2 ± 0.73 16.8 ± 1.16* 0.59 ± 0.05 1.41 ±0.05* 0.04 ± 0.02 0.18 ± 0.02*
4 12.0 ± 1.05 21.0 ± 1.38*# 13.8 ± 1.59 24.4 ± 1.54*# 10.4 ± 0.75 24.1 ± 2.32*# 0.58 ± 0.05 2.03 ± 0.06*# 0.07 ± 0.02 0.21 ± 0.01*
6 15.4 ± 1.57 28.6 ± 1.69*# 17.8 ± 1.39 39.4 ± 2.25*# 10.6 ± 1.40 34.4 ± 2.38*# 0.65 ± 0.06 2.65 ± 0.12*# 0.05 ± 0.02 0.22 ± 0.02*
8 13.6 ± 0.75 35.8 ± 1.93*# 17.0 ± 1.00 46.1 ± 1.79*# 11.8 ± 0.66 41.0 ± 1.95*# 0.67 ± 0.04 3.12 ± 0.23*# 0.07 ± 0.01 0.29 ± 0.02*
10 13.4 ± 1.03 40.8 ± 2.31*# 17.0 ± 1.76 53.8 ± 2.84*# 11.2 ± 0.84 46.0 ± 3.86*# 0.69 ± 0.05 3.60 ± 0.16*# 0.07 ± 0.02 0.34 ± 0.02*
12 15.6 ± 0.60 49.6 ± 2.11*# 16.8 ± 1.83 64.4 ± 3.30*# 12.2 ± 2.01 53.0 ± 4.37*# 0.71 ± 0.05 3.93 ± 0.05*# 0.10 ± 0.01 0.39 ± 0.02*
14 14.8 ± 1.62 60.6 ± 3.60*# 17.8 ± 1.5 85.4 ± 2.29*# 12.4 ± 0.51 62.6 ± 3.83*# 0.70 ± 0.02 4.28 ± 0.14*# 0.13 ± 0.01 0.44 ± 0.02*
  1. Data expressed as mean ± SE
  2. *Significant difference compared to control group at the same duration period by t test (P < 0.05)
  3. #Significant difference compared to the previous duration in the same group by paired t test (P < 0.05)